CEO Dan Honeywell comments:

“A year of transformation

In 2024, 2cureX underwent a major transformation following challenges with its distributor-led commercial strategy for IndiTreat®, which failed to meet revenue expectations. This led to leadership changes and the suspension of the strategy. In June, an investment consortium led by Kinled Group initiated a strategic restructuring, splitting 2cureX into two independent entities: 2cureX AB (publicly listed) and 2cureX A/S (privately held).

Under this new structure, 2cureX AB will focus on a Direct-to-Patient commercial approach and explore acquisitions, while 2cureX A/S will drive product development, aiming for CE-IVDR certification and expanded cancer indications. This dual-entity model enhances scalability, regulatory compliance, and global commercialization opportunities.

To lead this shift, Daniel Honeywell was appointed as CEO of 2cureX AB, effective December 2024. With expertise in digital health and precision oncology, he aims to accelerate growth, introduce new leadership, and establish an advisory board. The company remains committed to delivering value for both patients and investors.

Financial Overview

The financial position of 2cureX underwent a transformation during 2024, with the new structure and additional investment. At the close of 20243, our cash position stood at MSEK 5.1, and further investment is expected during 2025, to fund the new strategy.”

Second half year of 2024 (2024-07-01 until 2024-12-31) – the group

The result before tax was -3 249 KSEK (-1 225 KSEK)
The result per share* was -0.10 SEK (-0.07 SEK)
The solidity** was 66 % (93 %).
The cash and bank were 5 140 KSEK (1 459 KSEK).